Please assess the completion status of the following clinical trial:

Trial Title: Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of Enthesitis-related arthritis (ERA) or Juvenile psoriatic arthritis (JPsA) according to the International League of Associations for Rheumatology (ILAR) classification criteria of at least 6 months duration.~2. Active disease (ERA or JPsA) defined as having both:~   * at least 3 active joints~  * at least 1 site of active enthesitis at baseline or documented by history.~3. Inadequate response (at least 1 month) or intolerance to at least 1 nonsteroidal anti-inflammatory drugs(NSAID)~4. Inadequate response (at least 2 months) or intolerance to at least 1 Disease-modifying antirheumatic drugs (DMARD)~5. No concomitant use of second line agents such as disease-modifying and/or immunosuppressive drugs.~Exclusion Criteria:~1. Patients fulfilling any ILAR diagnostic JIA category other than ERA or JPsA.~2. Patients who have ever received biologic immunomodulating agents~3. Patients taking any non-biologic DMARD except for MTX (or sulfasalazine for ERA patients only).~4. Patients with active uncontrolled inflammatory bowel disease or active uncontrolled uveitis.~Other protocol-defined inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Period 2 - active (Type: EXPERIMENTAL): secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
- Treatment Period 2 - placebo (Type: PLACEBO_COMPARATOR): placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1

Based on this trial design, predict the completion outcome and termination type (if applicable).